Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities
Thomas R. Coleman(University of Messina), Michael Brines(Northwell Health), Anthony Cerami(Araim Pharmaceuticals (United States)), Zhuma Hu(Dalhousie University), Livius V. d’Uscio(Mayo Clinic), Rutger J. Ploeg(University of Oxford), Adriana Zanetti(Mario Negri Institute for Pharmacological Research), Pietro Ghezzi(Brighton and Sussex Medical School), Florian Tögel(University of Utah), LeAnne Swenson(University of Utah), Christof Westenfelder(Symbio FCell (France)), Zvonimir S. Katušić(Mayo Clinic), Ying Yang(Shanghai Jiao Tong University), Henri G. D. Leuvenink(Network for Earthquake Engineering Simulation), Norma E. Fox(University of California San Diego), Kenneth Kaushansky(Stony Brook School)
Cited by 127
Related Papers
A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 -Deficient Mice
|Cell|1996|1.5k
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Clinical Relevance of Biomarkers of Oxidative Stress
|Antioxidants and Redox Signaling|2015|906